China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies.
China imposed on 10 April an 84% tariff on all imported goods originating from the US, in response to the US’s earlier announced 84% reciprocal tariff on Chinese exports to the US – which has now been elevated to
Key Takeaways
- China’s 84% retaliatory tariffs on all imported goods from the US means manufacturing of US-originated drugs in China will make more sense than ever for some local licensees.
- Zai Lab has already decided to localize the manufacturing of three innovative, US-origin products, including Cobenfy (KarXT) from Bristol Myers Squibb/Karuna
